Targeted Therapy in Metastatic Colorectal Cancer (mCRC): Routine Addition vs Last Resort
J
oin moderator Dr Jonathan Mizrahi and Drs Sakti Chakrabarti and Tiago Biachi for a dynamic debate on whether to initiate targeted therapy early or reserve it for later lines of treatment. The session explores current strategies, key decision factors, and practical considerations in real-world patient management.
In this round, Drs Chakrabarti and Biachi examine how to approach targeted therapy in patients with limited marrow reserve—balancing risks, adjusting doses, and applying clinical data to everyday care.
In this round, Drs Chakrabarti and Biachi explore quality-of-life considerations during treatment, including proactive symptom management and workflow adjustments that support patient adherence and well-being.
Closing the debate, Drs Chakrabarti and Biachi discuss case-based decision-making and evolving treatment pathways, focusing on how clinicians can navigate sequencing and access challenges in modern oncology practice.
©2025 HMP Global. This is a non-CME activity. The views and opinions expressed by the presenter(s) do not necessarily reflect the views and opinions of the Oncology Learning Network, HMP Global, or its employees and affiliates.
